Join Our Crew

Scientist, Analytical Development

Philadelphia, PA

About the Position

Reporting to the Director, Analytical Development, this experienced and motivated Scientist will support phase-appropriate activities of analytical assays to CAAR-T manufacturing production, lentiviral vector production, new gene transfer/gene editing methodologies and clinical programs.

Responsibilities Include

  • Optimize, qualify, and validate analytical methods utilizing flow cytometry, qPCR/digital PCR, cytotoxicity, ELISA or other advanced technologies, as required to evaluate purity, identity, potency of lentiviral vectors and CAAR-T cells.
  • Execute quality control assays to analyze lentiviral vectors and CAAR-T cells manufactured by external partners.
  • Develop new analytical tests to assess advanced gene transfer and gene editing modalities.
  • Assist to author analytical development report, assay validation report and other technical documents for technical correctness and regulatory compliance.
  • Participate in technical troubleshooting and problem investigation.
  • Prepare, evaluate, and present data internally to cross functional teams.

Required Qualifications

  • Master’s degree in Biology or closely related discipline, and with 3-5 years of experience or Ph.D. with 1 + years of experience within a relevant industry
  • Relevant hands-on experience with flow cytometry, qPCR/ddPCR and ELISA.
  • Experience with analytical assay development or quality control programs for cell or gene therapy products, including lentiviral vectors or CAR-T products.
  • Must be highly organized and able to work independently.
  • Must be able to clearly communicate in writing, must have a desire to be part of a growing organization that uses cutting-edge science.
  • A high level of flexibility to support various other activities and ability to learn new techniques outside of existing field of expertise.
  • Strong team orientation, science curiosity and passion for continuous self-development.
  • Strong laboratory documentation experience.
  • Familiar with GLP/GMP requirements of biopharmaceutical manufacturing.

How to Apply

Please email directly to submit an application.

Please include your CV along with the title of the position you are applying for.


Our most important asset is our people and we offer competitive benefits including health and retirement, PTO, and stock option plans.

Equal Opportunity Employer

Cabaletta Bio is an equal opportunity employer. We do not discriminate on the basis of race, color, gender, gender identity, sexual orientation, age, religion, national or ethnic origin, disability, protected veteran status or any other basis protected by applicable law.

About Cabaletta Bio

Cabaletta Bio (NASDAQ: CABA) is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-expressing B cells while sparing normal antibody-expressing B cells, which are essential for human health. Cabaletta’s Approach for selective B cell Ablation platform, called our CABA™ platform, has applicability across more than two dozen B cell-mediated autoimmune diseases that we have identified, reviewed and prioritized. CAAR T technology is based on the revolutionary Chimeric Antigen Receptor (CAR) T cell technology developed at the University of Pennsylvania that resulted in one of the first commercially-available CAR T cell products for the treatment of B cell malignancies. Cabaletta has an exclusive global licensing agreement and multiple sponsored research agreements with the University of Pennsylvania to develop CAAR T technology to treat B cell-mediated autoimmune diseases.

The Company’s lead product candidate, DSG3-CAART, received IND clearance from the FDA in September 2019, and initial safety data in clinical trials has been reported. DSG3-CAART is designed to be a potential treatment for patients with mucosal pemphigus vulgaris (mPV), which is a rare autoimmune blistering disorder that causes painful blisters and sores on mucous membranes leading to severe and sometimes debilitating and life-altering effects. Cabaletta Bio is also pursuing additional pipeline candidates for other B cell mediated disorders including MuSK Myasthenia Gravis (MG) with an IND planned for 2H 2021, mucocutaneous PV, PLA2R positive membranous nephropathy (PMN), and Factor VIII inhibitors.

Uniquely Differentiated. Rapid. Elegant.

At Cabaletta, we are driven by the shared mission of developing a new type of therapy, where patients’ own cells are used to fight disease. We are building a culture grounded in the knowledge that success in the Cabaletta mission lies in the hands of individuals across every aspect of the company. To nurture this, we make an active commitment to the well-being and continuous growth of each person who joins our team. In this way, we are not only working to improve the lives of patients, but of everyone involved. #CabalettaCrew